Standard Amblyopia Therapy in Adult Amblyopes

NCT ID: NCT03341780

Last Updated: 2017-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-16

Study Completion Date

2016-10-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Amblyopia is characterized by a reduction in visual acuity, contrast sensitivity, and binocular visual functions. The two main causes of amblyopia are anisometropia and strabismus which alter the synaptic connections between neurons along the visual pathway. Current treatment for amblyopia has indicated that the younger the amblyope, the greater the effect of treatment. The purpose of this study is to determine if standard amblyopia treatment improved visual acuity in adult amblyopes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Functional amblyopia is an optically uncorrectable decrease in visual acuity, i.e., spatial resolution, with no apparent pathological or morphological cause. There are several etiological origins for amblyopia in the human population; anisometropia and strabismus are the two most prevalent etiological factors. Anisometropic amblyopia is a decrease in visual acuity (spatial resolution) that is the result of a large difference in refractive error between the two eyes. Strabismic amblyopia is characterized by an eye misalignment early in life which is associated with a decrease in visual acuity.

The initial site of the defect in amblyopia is the primary visual cortex. The amblyopic eye is placed at a competitive disadvantage to the nonamblyopic eye which results in a reduction in the synapses or cells responding to the amblyopic eye. The conditions associated with amblyopia must be present prior to the end of the critical period of neural development for amblyopia to develop. The neurophysiological systems of anisometropic and strabismic monkeys have differences in the distributions of binocular cortical cells. Anisometropic amblyopic monkeys only exhibit binocular cells that are tuned to low spatial frequencies. If a neuron has a high spatial resolution, it is unlikely that the neuron will be binocular. However, strabismic amblyopic monkeys exhibit few binocular cells and, moreover, there does not appear to be a spatial frequency dependent distribution of these binocular cells. The strabismic subjects typically displayed few binocular cells, regardless of the spatial frequency tuning of the cell.

If the amblyopic eye is compared to the nonamblyopic eye, two important differences are noted. First, the amblyopic eye has a lower contrast sensitivity at high spatial frequencies (and sometimes at all spatial frequencies) than the nonamblyopic eye. This also results in a decrease in visual acuity for the amblyopic eye. Second, the amblyopic eye demonstrates a longer latency for neural transmission than the nonamblyopic eye.

There is very little published on adult amblyopia therapy. This is because clinicians initially believed that amblyopia could not be treated after the end of the critical period. The prevailing theory was that the synaptic contacts between cells could only be modified during the critical period. In children, the majority of the improvement in acuity (80%) takes place in the first 6 weeks of therapy. There is a direct relationship between the hours of patching and the improvement in acuity. Most of the improvement in acuity occurs after the first 100 hours of patching.

There is a linear dose-response function for amblyopia treatment. The logMAR acuity increases 0.1 log unit or 1 chart line per 120 hours of patching. The response does not differ between the types of amblyopia. It has also been demonstrated that there is only a minimal benefit to patching more than 2 hours/day.

In a Pediatric Eye Disease Investigator Group (PEDIG) study, 189 amblyopic children were treated with 2 hours of patching per day. The amblyopic eye acuities ranged from 20/40 - 20/80 before treatment. The average improvement in acuity after 4 months of treatment was 0.24 logMAR (2.4 lines improvement on a logMAR chart). Another study used amblyopes with poorer acuity (20/100 - 20/400 before therapy). After 4 months of patching, the average increase in acuity was 0.48 logMAR (or an increase of 4.8 lines on a logMAR chart). The average acuity went from 20/250 (i.e., 1.10 logMAR) before treatment to 20/63 (i.e., 0.50 logMAR) after treatment. The results were the same for anisometropic amblyopes and strabismic amblyopes. In another study with amblyopes with starting acuity worse than 20/100, the improvement was 3.7 ± 2.5 logMAR chart lines of acuity.

Recent studies have suggested that adult amblyopia can be treated with non-standard therapy. Patching combined with active, near, threshold-training tasks and continuous feedback is employed in these studies. These studies indicate that amblyopia can be treated after the critical period ends. It is suggested that these perceptual learning tasks improve performance in the amblyopic eye by decreasing neural noise. Standard amblyopia therapy typically employed in children has not been investigated in adult amblyopes. The purpose of this study is to use standard amblyopic therapy to determine if there is an enhancement in visual performance in the amblyopic eye of adults.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amblyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

amblyopia therapy

Any of the following amblyopia training activities may be employed during patching: board games, card games, coloring in O's, comic books, craft projects, crossword puzzles, dot-to-dot patterns, drawing, hammering nails, jacks, jigsaw puzzles, lego and other blocks, marbles, mazes, peg-board activities, perceptual materials, pickup sticks, reading, sewing, shooting games, stringing beads, throwing or hitting games, tracing, and video or computer games.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Amblyopic patients with acuities between 20/40 (0.30 logMAR) and 20/400 (1.30 logMAR).
* All subjects will be over the age of 18.

Exclusion Criteria

* Subjects will be recruited from the College community and University Eye Clinic.


* A significant cataract that affects vision.
* Glaucoma, diabetes, uncontrolled high blood pressure.
* Other ocular or systemic diseases that will affect visual acuity.
* The inability to give informed consent.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allergan

INDUSTRY

Sponsor Role collaborator

Southern California College of Optometry at Marshall B. Ketchum University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Ridder, OD, PhD

Role: PRINCIPAL_INVESTIGATOR

Southern California College of Optometry at Marshall B. Ketchum University

References

Explore related publications, articles, or registry entries linked to this study.

von Noorden GK. Amblyopia: a multidisciplinary approach. Proctor lecture. Invest Ophthalmol Vis Sci. 1985 Dec;26(12):1704-16.

Reference Type BACKGROUND
PMID: 3934105 (View on PubMed)

Michaels DD. Visual optics and refraction: a clinical approach. St Louis, MO: C.V. Mosby Co.; 1980.

Reference Type BACKGROUND

Crawford ML, Blake R, Cool SJ, von Noorden GK. Physiological consequences of unilateral and bilateral eye closure in macaque monkeys: some further observations. Brain Res. 1975 Jan 24;84(1):150-4. doi: 10.1016/0006-8993(75)90809-4. No abstract available.

Reference Type BACKGROUND
PMID: 1111823 (View on PubMed)

Hubel DH, Wiesel TN, LeVay S. Plasticity of ocular dominance columns in monkey striate cortex. Philos Trans R Soc Lond B Biol Sci. 1977 Apr 26;278(961):377-409. doi: 10.1098/rstb.1977.0050. No abstract available.

Reference Type BACKGROUND
PMID: 19791 (View on PubMed)

Stewart CE, Moseley MJ, Stephens DA, Fielder AR. Treatment dose-response in amblyopia therapy: the Monitored Occlusion Treatment of Amblyopia Study (MOTAS). Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3048-54. doi: 10.1167/iovs.04-0250.

Reference Type BACKGROUND
PMID: 15326120 (View on PubMed)

Repka MX, Beck RW, Holmes JM, Birch EE, Chandler DL, Cotter SA, Hertle RW, Kraker RT, Moke PS, Quinn GE, Scheiman MM; Pediatric Eye Disease Investigator Group. A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol. 2003 May;121(5):603-11. doi: 10.1001/archopht.121.5.603.

Reference Type BACKGROUND
PMID: 12742836 (View on PubMed)

Holmes JM, Kraker RT, Beck RW, Birch EE, Cotter SA, Everett DF, Hertle RW, Quinn GE, Repka MX, Scheiman MM, Wallace DK; Pediatric Eye Disease Investigator Group. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology. 2003 Nov;110(11):2075-87. doi: 10.1016/j.ophtha.2003.08.001.

Reference Type BACKGROUND
PMID: 14597512 (View on PubMed)

Holmes JM, Edwards AR, Beck RW, Arnold RW, Johnson DA, Klimek DL, Kraker RT, Lee KA, Lyon DW, Nosel ER, Repka MX, Sala NA, Silbert DI, Tamkins S; Pediatric Eye Disease Investigator Group. A randomized pilot study of near activities versus non-near activities during patching therapy for amblyopia. J AAPOS. 2005 Apr;9(2):129-36. doi: 10.1016/j.jaapos.2004.12.014.

Reference Type BACKGROUND
PMID: 15838439 (View on PubMed)

Holmes JM, Lazar EL, Melia BM, Astle WF, Dagi LR, Donahue SP, Frazier MG, Hertle RW, Repka MX, Quinn GE, Weise KK; Pediatric Eye Disease Investigator Group. Effect of age on response to amblyopia treatment in children. Arch Ophthalmol. 2011 Nov;129(11):1451-7. doi: 10.1001/archophthalmol.2011.179. Epub 2011 Jul 11.

Reference Type BACKGROUND
PMID: 21746970 (View on PubMed)

Levi DM, Li RW. Perceptual learning as a potential treatment for amblyopia: a mini-review. Vision Res. 2009 Oct;49(21):2535-49. doi: 10.1016/j.visres.2009.02.010. Epub 2009 Feb 27.

Reference Type BACKGROUND
PMID: 19250947 (View on PubMed)

Levi DM, Li RW. Improving the performance of the amblyopic visual system. Philos Trans R Soc Lond B Biol Sci. 2009 Feb 12;364(1515):399-407. doi: 10.1098/rstb.2008.0203.

Reference Type BACKGROUND
PMID: 19008199 (View on PubMed)

Ridder WH 3rd, Rouse MW. Predicting potential acuities in amblyopes: predicting post-therapy acuity in amblyopes. Doc Ophthalmol. 2007 May;114(3):135-45. doi: 10.1007/s10633-007-9048-y. Epub 2007 Feb 20.

Reference Type BACKGROUND
PMID: 17310345 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SoutherCCO

Identifier Type: -

Identifier Source: org_study_id